Generation of Anti-TIGIT Antibodies using Bio-Rad’s New Pioneer Antibody Discovery Platform
sponsored by Bio-Rad Laboratories
We are excited to invite you to an exclusive webinar that delves into the cutting-edge world of antibody drug discovery!
Join us as we explore the Pioneer Antibody Discovery Platform, an innovative solution that revolutionizes the field of biotherapeutics with its state-of-art phage display library.
Paul Royle, PhD will introduce the key features that set the Pioneer Antibody Discovery Platform apart from traditional methods of antibody discovery. You will learn how a 225 billion unique sequence library unleashes unprecedented diversity of antibody candidates with exceptional affinity and developability.
SpyLock selection technology will be introduced, which is available in Pioneer Platform to ensure the rapid generation of bi-specific antibodies for high-throughput screening. Case study on anti-TIGIT antibodies show that the performance of lead candidates from Pioneer is comparable with several antibodies currently undergoing clinical trials.
Webinar Learning Objectives:
- Pioneer is an antibody drug discovery platform featuring a Fab phage display library with 225 billion unique sequences.
- Bio-Rad's Pioneer Antibody Discovery Platform delivers antibody leads with exceptional affinity, high diversity and great developability.
- Advantages of Pioneer over in vivo discovery approaches are short timeline, animal-free, less limitations on antigen types, easy-to-manipulate screening conditions, et al.
